Analyst Price Targets — SLAB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 6, 2026 4:02 pm | Craig Hettenbach | Morgan Stanley | $231.00 | $207.48 | TheFly | Silicon Labs price target raised to $231 from $147 at Morgan Stanley |
| February 5, 2026 1:04 pm | — | UBS | $205.00 | $203.44 | TheFly | Silicon Labs price target raised to $205 from $160 at RBC Capital |
| February 5, 2026 10:47 am | Tom O'Malley | Barclays | $231.00 | $203.41 | TheFly | Silicon Labs price target raised to $231 from $130 at Barclays |
| February 4, 2026 6:04 pm | — | Stifel Nicolaus | $231.00 | $203.29 | TheFly | Silicon Labs downgraded to Hold from Buy at Stifel |
| January 14, 2026 9:26 pm | — | RBC Capital | $160.00 | $149.05 | TheFly | Silicon Labs initiated with a Sector Perform at RBC Capital |
| October 6, 2025 7:54 pm | Tore Svanberg | Stifel Nicolaus | $165.00 | $135.13 | TheFly | Silicon Labs price target raised to $165 from $160 at Stifel |
| August 5, 2025 5:52 pm | Tom O'Malley | Barclays | $130.00 | $126.76 | TheFly | Silicon Labs price target raised to $130 from $100 at Barclays |
| May 14, 2025 9:51 am | Tom O'Malley | Barclays | $100.00 | $126.31 | TheFly | Silicon Labs price target raised to $100 from $80 at Barclays |
| November 5, 2024 12:10 pm | Rajvindra Gill | Needham | $120.00 | $104.46 | StreetInsider | Silicon Labs (SLAB) PT Lowered to $120 at Needham |
| November 5, 2024 5:15 am | John Vinh | KeyBanc | $115.00 | $104.46 | StreetInsider | Silicon Labs (SLAB) PT Lowered to $115 at KeyBanc |
Latest News for SLAB
Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) CEO, Dr Eric Leire, talked with Proactive about encouraging results from the SLAB (Sarcopenia and Longevity in Aged Beagles) trial, highlighting sustained efficacy and safety following treatment. Leire explained that one of the most significant findings is the durability of the therapy's effects.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5), the European biotechnology company focused on gene therapies for age-related diseases, has reported that positive safety and efficacy signals from its SLAB trial have been maintained three months after the initial dosing period, with no adverse events observed. The SLAB (Sarcopenia and Longevity in Aged Beagles) trial is evaluating Genflow's proprietary SIRT6…
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Silicon Laboratories Inc. (NasdaqGS: SLAB) to Texas Instruments Incorporated (NasdaqGS: TXN). Under the terms of the proposed transaction, shareholders of Silicon will receive $231.00 in cash for each share of Silicon…
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SLAB.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.